# Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM

> **NCT05909826** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Dong-A University Hospital** · enrollment: 49 (estimated)

## Conditions studied

- Multiple Myeloma in Relapse
- Multiple Myeloma, Refractory

## Interventions

- **DRUG:** Carfilzomib
- **DRUG:** Cyclophosphamide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT05909826
- **Lead sponsor:** Dong-A University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-07-01
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05909826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05909826, "Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT05909826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*